Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension - Full Text View

Purpose

The purpose of this study is to determine whether the study drug is effective in the long-term treatment of primary or secondary pulmonary hypertension

Condition	Intervention	Phase
Hypertension, Pulmonary	Drug: Ventavis (Iloprost, BAYQ6256)	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	An Explorative, Open-Label, Multicenter, Randomized, Parallel-Group Comparative Study of Safety, Tolerability, and the Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension Over 2 Years

Resource links provided by NLM:

MedlinePlus related topics: Pulmonary Hypertension

Drug Information available for: Iloprost

U.S. FDA Resources

Further study details as provided by Bayer:

Primary Outcome Measures:

Tolerability: Adverse events (AE) and safety variables, Variables to describe clinical effects: NYHA class, Walking distance (6-min walk), Mahler Dyspnea Index, EuroQoL, Karnofsky Index, Hemodynamic and gas exchange
Mortality and lung/heart-lung transplantation, Acute effects of iloprost inhalation on hemodynamics and gas exchange

Secondary Outcome Measures:

Overall clinical tolerability of the long-term use of iloprost aerosol
Serious Adverse Events and deaths
Effect of long-term administration of inhaled iloprost on mortality and transplantation
Exercise capacity
Acute effect of inhaled iloprost on hemodynamics and gas exchange
Effects of long-term administration of inhaled iloprost on hemodynamics and gas exchange
Quality of Life


Enrollment:	63
Study Start Date:	July 1998
Study Completion Date:	May 2001

Arms	Assigned Interventions
Experimental: Arm 1	Drug: Ventavis (Iloprost, BAYQ6256)

Detailed Description:

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Eligibility


Ages Eligible for Study:	18 Years to 70 Years (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female patients
Secondary pulmonary hypertension
Mean pulmonary artery pressure equal or above 40 mmHg or primary pulmonary hypertension with a pressure equal or above 30 mmHg while resting during appropriate conventional treatment
Written informed consent after having been duly informed about all diagnostic and therapeutic measures involved in the study

Exclusion Criteria:

Clinical Instability at baseline
Pulmonary venous obstruction
Global respiratory insufficiency
Obstructive ventilation disorders, Interstitial pulmonary disease
Cerebrovascular events
Myocardial infarction or major cardiac surgery within 3 months prior to baseline
Bleeding disorders or bleeding risk
Severe hepatic insufficiency or renal insufficiency
Malignant diseases
HIV positive
Pregnancy, female patients of child-bearing potential without adequate contraception and nursing mothers
Congenital or acquired valvular defects and myocardial function disorders not related to pulmonary hypertension
Prior pulmonary embolism
Collagenosis
Pulmonary arterial or valvular stenosis

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00414687

Sponsors and Collaborators

Bayer

Investigators


Study Director:	Bayer Study Director	Bayer

More Information

Additional Information:

Click here and search for drug information provided by the FDA This link exits the ClinicalTrials.gov site

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Olschewski H, Hoeper MM, Behr J, Ewert R, Meyer A, Borst MM, Winkler J, Pfeifer M, Wilkens H, Ghofrani HA, Nikkho S, Seeger W. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010 May;104(5):731-40. doi: 10.1016/j.rmed.2010.01.008. Epub 2010 Feb 11.


Responsible Party:	Therapeutic Area Head, Bayer Schering Pharma AG
ClinicalTrials.gov Identifier:	NCT00414687 History of Changes
Other Study ID Numbers:	90427 300341
Study First Received:	December 20, 2006
Last Updated:	May 14, 2009
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Bayer:


Primary or secondary Pulmonary hypertension Iloprost Inhaled Long-term treatment

Additional relevant MeSH terms:


Hypertension Hypertension, Pulmonary Vascular Diseases Cardiovascular Diseases Lung Diseases	Respiratory Tract Diseases Iloprost Platelet Aggregation Inhibitors Vasodilator Agents

ClinicalTrials.gov processed this record on September 23, 2016